Weiss Ratings Reaffirms Sell (E+) Rating for Mural Oncology (NASDAQ:MURA)

Mural Oncology (NASDAQ:MURA)‘s stock had its “sell (e+)” rating reaffirmed by investment analysts at Weiss Ratings in a report released on Friday,Weiss Ratings reports.

Separately, Wall Street Zen lowered shares of Mural Oncology from a “hold” rating to a “strong sell” rating in a research report on Sunday, August 10th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $12.00.

Mural Oncology Trading Down 0.5%

NASDAQ:MURA opened at $2.09 on Friday. Mural Oncology has a 1 year low of $0.95 and a 1 year high of $4.74. The firm’s fifty day simple moving average is $2.08 and its 200 day simple moving average is $2.31. The firm has a market capitalization of $36.22 million, a PE ratio of -0.24 and a beta of 2.93.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings results on Monday, August 4th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.13) by ($0.64). As a group, analysts anticipate that Mural Oncology will post -7.54 EPS for the current fiscal year.

Institutional Trading of Mural Oncology

Several institutional investors have recently made changes to their positions in the business. Armistice Capital LLC boosted its position in shares of Mural Oncology by 1.3% during the 1st quarter. Armistice Capital LLC now owns 1,722,000 shares of the company’s stock valued at $2,170,000 after acquiring an additional 22,000 shares in the last quarter. Soleus Capital Management L.P. acquired a new stake in shares of Mural Oncology during the 2nd quarter valued at about $3,270,000. Orbimed Advisors LLC acquired a new stake in shares of Mural Oncology during the 2nd quarter valued at about $1,454,000. LMR Partners LLP acquired a new stake in shares of Mural Oncology during the 2nd quarter valued at about $1,276,000. Finally, Diametric Capital LP acquired a new stake in shares of Mural Oncology during the 2nd quarter valued at about $864,000. 80.21% of the stock is currently owned by institutional investors and hedge funds.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.